AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05385575
Drug: KN056 (18.0mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive assigned single dose of KN056 or placebo on Day 1
Trial: NCT05981703
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered in accordance with relevant local guidelines and/or prescribing information.
Trial: NCT06679764
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pataints received opioid analgesia with genaral anesthesia
Trial: NCT06605131
Drug: GP+CCRT
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Induction Chemotherapy (GP Regimen ): Gemcitabine: 1000 mg/m² on Day 1 and Day 8; Cisplatin (DDP): 80 mg/m² on Day 1-3; every 3 weeks for 3 cycles.~2. Concurrent Chemoradiotherapy (CCRT): Cisplatin (DDP): 100 mg/m², starting on the first day of radiotherapy; every 3 weeks for 3 cycles
Trial: NCT00110734
Drug: S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05607563
Drug: PM1009 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive PM1009 intravenously, every 2 weeks
Trial: NCT05094596
Drug: Standart treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (n=60) received standard treatment in accordance with our national COVID-19 diagnosis and treatment guide.
Trial: NCT05103657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05601778
Drug: HSK31858
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 24-week treatment period in patients with non-cystic fibrosis bronchiectasis
Trial: NCT05601778
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the placebo comparator of study
Trial: NCT04736758
Drug: GP681 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.
Trial: NCT04736758
Drug: GP681 Simulant
RxNorm normalized name: STAPHYLOCOCCUS SIMULANS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: influenza subjects is randomized 1:1:1 into GP681 tablet 40mg group,GP681 tablet 20mg group and Placebo group,with 72 patients in each group.subjects is given with GP681 tablet or GP681 Simulant only once to treat influenza.
Trial: NCT05528679
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered subcutaneously Q4W
Trial: NCT06608940
Drug: BC3402
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BC3402, intravenous, 20 mg/kg, D1 and D15 of every 28 day cycle, continuous. BC3402 to be administered after completion of the infusion of durvalumab and/or tremelimumab on the days when BC3402 is to be administered with durvalumab and/or tremelimumab
Trial: NCT01004315
Drug: KUC-7483
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01004315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05471609
Drug: levodopa/carbidopa oral formulation A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outer sachet 100mg CD/100mg LD and inner sachet 0mg CD /300mg LD
Trial: NCT05471609
Drug: levodopa/carbidopa oral formulation B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outer sachet 100mg CD/0mg LD and inner sachet 0mg CD /400mg LD
Trial: NCT05471609
Drug: levodopa/carbidopa oral formulation C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outer sachet 50mg CD/200mg LD and inner sachet 50mg CD /200mg LD
Trial: NCT05739734
Drug: CRIS100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: local application of CRIS100
Trial: NCT05547906
Drug: ASCA101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion Twice a Week, 8 times per each Cycle
Trial: NCT05620563
Drug: LY3857210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05620563
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04835441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded placebo matching ALPN-101 will be administered.
Trial: NCT04540692
Drug: Cyclophosphamide + Doxorrubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will start with Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days for 3 cycles
Trial: NCT05368558
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT05694130
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisolone 1mg/kg daily for 4 weeks, then tapered to 7.5mg in 8 weeks.
Trial: NCT06384482
Drug: SNC115 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNC115 Injection is DLL3 CART.
Trial: NCT04830241
Drug: Antidepressant
RxNorm normalized name: Antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of neonatal hypotonia newborns following in utero exposure to antidepressant drugs, with a chronology compatible with the drug toxicity
Trial: NCT06299033
Drug: hNPC01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hNPC01, human forebrain neural progenitor cell product, intracerebral injection
Trial: NCT06474481
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (C), 750 mg/m2, IV, D2; for 4-6 cycles for CHOP treatment , 1 cycle = 28 days
Trial: NCT06474481
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (H), 50 mg/m2, IV, D2; for 4-6 cycles for CHOP treatment ，1 cycle = 28 days
Trial: NCT06458244
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy for AML consolidation treatment
Trial: NCT05268419
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhalation of 35%-ethanol spray
Trial: NCT06210945
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06204016
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be administered as placebo-controlled condition (P-Tabletten White 7mm, Lichtenstein)
Trial: NCT04868565
Drug: Caffeine Citrate 20 MG/1 ML Intravenous Solution [CAFCIT]
RxNorm normalized name: Caffeine Citrate 20 MG/1 ML Intravenous Solution [CAFCIT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: after randomization, caffeine citrate will be contineously prescribed to those patients assigned to the ongoing caffeine with oxygen supplement (group 2) with a medication regimen of 10mg/kg.dose, once daily, and weekly adjustment based on the working weight.
Trial: NCT06606886
Drug: Tablet Hydroxyurea (Group B)
RxNorm normalized name: hydroxyurea Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet Hydroxyurea 10-20mg/kg once daily orally with breakfast for 1 year
Trial: NCT06608433
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills will be administered as a single oral dose
Trial: NCT04703842
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRD-001 matching placebo
Trial: NCT06285240
Drug: MK-1167
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg and 5 mg oral capsules
Trial: NCT06285240
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1167 matching placebo administered oral capsules
Trial: NCT06533280
Drug: Part A, C and D: VH3739937 500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of VH3739937 in moderate fat/moderate calorie conditions
Trial: NCT06533280
Drug: Part A: VH3739937 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of VH3739937 in moderate fat/moderate calorie conditions.
Trial: NCT06533280
Drug: Part A and C: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of Placebo in moderate fat/moderate calorie conditions
Trial: NCT06533280
Drug: Part B: Treatment A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VH3739937, 500 mg(single dose given as 5 x 100 mg tablets). administered under moderate fat/moderate calorie conditions (reference)
Trial: NCT06533280
Drug: Part B: Treatment B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VH3739937, 500 mg (single dose given as 500 mg tablet) administered under moderate fat/moderate calorie conditions (test)
Trial: NCT06533280
Drug: Part B: Treatment C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VH3739937, 500 mg single tablet administered under fasted conditions.
Trial: NCT06533280
Drug: Part B: Treatment D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VH3739937, 500 mg single tablet administered under low-fat/ low calorie conditions.
Trial: NCT06533280
Drug: Part B: Treatment E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VH3739937, 500 mg single tablet administered under high-fat/ high calorie conditions.
Trial: NCT06533280
Drug: Part D: Probe cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of probe cocktail (Midazolam, Digoxin, Total Dabigatran etexilate, Rosuvastatin) in moderate fat/moderate calorie conditions.
Trial: NCT06679465
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 puffs placebo
Trial: NCT06106334
Drug: S309309
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as oral capsules
Trial: NCT04792489
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lymphodepleting chemotherapy
Trial: NCT05135624
Drug: SP16 (6mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP16 will be administered as 2 concurrent, separate 2 mL s.c injections of 3mg/mL SP16
Trial: NCT05135624
Drug: SP16 (12 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP16 will be administered as a single 2 mL s.c. injection of 3 mg/mL SP16 and 1 concurrent separate 2 mL s.c. injection of sterile water
Trial: NCT06312423
Drug: Oligonucleotides, Phosphorothioate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: 20 mg/day single dose Group 2: 20 mg/day for 3 days Group 3: 20 mg/day for 5 days
Trial: NCT04902872
Drug: CBX-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBX-12 is an alphalex construct which consists of a low-pH insertion peptide, a self-immolating linker, and exatecan as the pharmacologically active moiety
Trial: NCT05904691
Drug: OCU-10-C-110 for Injection
RxNorm normalized name: Tru-Blu C-Hex 110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCU-10-C-110 for Injection in one of 3 doses
Trial: NCT05531682
Drug: HB0017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive HB0017 in different dosing regimens
Trial: NCT05925725
Drug: • harpagozid • boswellin = LOXACON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy
Trial: NCT04691700
Drug: Goreisan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add Goreisan 7.5g per day to standard treatment with the intention to reduce or discontinue the existing diuretics
Trial: NCT05015127
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05015127
Drug: HBM9161 680 mg qw by q2w from week 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBM9161 680 mg qw by q2w from week 7
Trial: NCT05015127
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo qw by HBM9161 680mg qw from week 12
Trial: NCT05643508
Drug: (P) DWC202206
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of DWC202206 A mg
Trial: NCT05643508
Drug: (P) DWC202207
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of DWC202207 B/C mg
Trial: NCT06123026
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 encapsulated placebo tablet given to participants after procedure
Trial: NCT04819854
Drug: EP395
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: capsule for oral treatment
Trial: NCT04819854
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule for oral treatment
Trial: NCT06467201
Drug: KSHN001126 150mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 subjects will receive single oral dose of 150mg
Trial: NCT06467201
Drug: KSHN001126 300mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 subjects will receive single oral dose of 300mg
Trial: NCT06467201
Drug: KSHN001126 600mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 subjects will receive single oral dose of 600mg
Trial: NCT05397795
Drug: 10000 IU hCG (Choriomon5000 IU; IBSA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10000 IU of hCG (Choriomon5000 IU; IBSA) given intramuscularly
Trial: NCT05021484
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion in regular intervals over 6 months
Trial: NCT04291508
Drug: Intravenous Acetaminophen (room temperature)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen given intravenously at the dose of 1 gram (or 15 mg/kg if patient weighs \< 50 kg) every six hours for 5 days (20 doses)
Trial: NCT06025552
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of TU7710 at corresponding TU7710 dose level. In each dose level, 2 subjects will be assigned to placebo group.
Trial: NCT04323462
Drug: Diabetic DM
RxNorm normalized name: Diabetic DM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previously receiving OADs and/or basal insulin
Trial: NCT06295094
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.1 mg/m2 body surface in 50ml saline
Trial: NCT05249972
Drug: AKP02/AKVANO cutaneous spray (calcipotriol 50 μg/g + betamethasone 0.5 mg/g/ AKVANO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cutaneous spray
Trial: NCT05249972
Drug: Enstilar Topical Product (calcipotriol 50 μg/g + betamethasone 0.5 mg/g)
RxNorm normalized name: Enstilar Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical foam
Trial: NCT00006488
Drug: recombinant-methionyl human glial cell line-derived neurotrophic factor
RxNorm normalized name: brain-derived neurotrophic factor, human
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06596291
Drug: EG110A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants treated with EG110A
Trial: NCT04199572
Drug: Diclofenac and Paracetamol
RxNorm normalized name: Diclofenac and paracetamol and serrapeptase only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: analgesic effect of diclofenac along with either Oral versus Intravenous paracetamol versus placebo
Trial: NCT04862962
Drug: Rosuvastatin 10 or 20mg /Ezetimibe 10 mg Fixed Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablets 10 mg/10 mg or 20 mg/10 mg
Trial: NCT06614751
Drug: DAT-2645 tablet
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient will be randomized into 2 groups and take DAT-2645 tablet daily. dosage is optimal dose-1 or optimal dose-2, 21day/ Cycle. The subject of this part is to optimize dosage and definite RP2D.
Trial: NCT06614751
Drug: DAT-2645 tablet
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study set 6 dose level cohorts in dose escalation part.On C0D1, patient take DAT-2645 one time (Single use), The dosage is same as his enrolled cohort dose level. if no DLT, 7 days later(C1D1), patients will continue taking DAT-2645 tablet daily, dasage is same as before, 21days/cycle.
Trial: NCT05186779
Drug: Progestagen
RxNorm normalized name: vaginal ring with progestogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receiving treatment with any progestogen, including dydrogesterone, or other treatment in the first trimester of pregnancy following; (Cohort A) a diagnosis of early bleeding in pregnancy or recurrent pregnancy loss, or (Cohort B) following IVF/ART embryo transfer
Trial: NCT05143502
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Prednisolone 40 mg/day for two weeks.
Trial: NCT05387070
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is supplied as a solution containing the formulation buffer for TransCon PTH in a single-patient-use prefilled pen intended for subcutaneous injection.
Trial: NCT04968106
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin will administered by intravenous infusion on day 1 every 3 weeks (75 mg/m²) up to 3 cycles
Trial: NCT04968106
Drug: INCMGA00012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retifanlimab will be administered by intravenous infusion on day 1every 3 weeks (375 mg) up to 3 cycles
Trial: NCT05945667
Drug: Monural
RxNorm normalized name: Monuril Paediatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 sachet, only 1st day of trial
Trial: NCT04926545
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 3 cycles of FOLFIRI regimen for chemotherapy. Irinotecan intravenous (IV) infusion (180 mg/m2) through a drip into the bloodstream over 90 minutes. Folinic acid (400 mg/m2) IV infusion through a drip into the bloodstream over 2 hours. 5-fluorouracil (5-FU) IV bolus (400 mg/m2) into the bloodstream over 5 minutes, followed by 5-FU (2400 mg/m2) continuous IV infusion through a drip or pump into the bloodstream for 46-48 hours.
Trial: NCT05919745
Drug: Ibuprofen 600 mg
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Preoperative delivery of ibuprofen per os.
Trial: NCT05919745
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative delivery of placebo per os.
Trial: NCT05919745
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups will be given rescue medication in the form of 1,000 mg tabs of acetaminophen every 6 hours per os as needed for pain (maximum allowed daily dose 4,000 mg per FDA) and will be allowed to receive ibuprofen or other analgesic medication as needed if pain is not controlled by acetaminophen alone. The subjects will receive the rescue medication pills at the end of the surgical appointment.
Trial: NCT04767087
Drug: Nigella sativa seed
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/Kg/day
Trial: NCT06615700
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of NA-931
Trial: NCT05896215
Drug: KNP2002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dairy topical administration for 12 weeks
Trial: NCT05896215
Drug: Placebo of KNP2002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dairy topical administration for 12 weeks
Trial: NCT05453786
Drug: SID1903
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral administration of SID1903 after an overnight fast
Trial: NCT05453786
Drug: SID1903-R1/SID1903-R2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral administration of SID1903-R1 and SID1903-R2 after an overnight fast
Trial: NCT05227131
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine (1000 mg per square meter of body-surface area) will be administrated orally twice daily on days 1 to 14 of each 21-day cycle
Trial: NCT06123338
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine twice daily on days 1 to 14 every 3 weeks or 5-FU on days 1 to 5 every 3 weeks
Trial: NCT06598631
Drug: Volenrelaxin
RxNorm normalized name: Volenrelaxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06598631
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05190523
Drug: ASC42 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of ASC42 tablets orally once daily for 12 weeks.
Trial: NCT05190523
Drug: ASC42 15 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of ASC42 tablets orally once daily for 12 weeks.
Trial: NCT05190523
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets orally once daily for 12 weeks.
Trial: NCT06283121
Drug: SOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy phase: Oxaliplatin 130 mg，i.v., D1 and D3, 3 weeks per cycle; Tegafur 40\~60mg b.i.d. p.o. D1\~D14; 3 weeks per cycle